全文获取类型
收费全文 | 140篇 |
免费 | 11篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
基础医学 | 9篇 |
口腔科学 | 1篇 |
临床医学 | 8篇 |
内科学 | 91篇 |
特种医学 | 11篇 |
外科学 | 7篇 |
综合类 | 4篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 14篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 2篇 |
2019年 | 8篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 8篇 |
2013年 | 8篇 |
2012年 | 6篇 |
2011年 | 6篇 |
2010年 | 10篇 |
2009年 | 9篇 |
2008年 | 5篇 |
2007年 | 11篇 |
2006年 | 12篇 |
2005年 | 7篇 |
2004年 | 8篇 |
2003年 | 7篇 |
2002年 | 3篇 |
2001年 | 2篇 |
1998年 | 1篇 |
1996年 | 2篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1989年 | 2篇 |
1987年 | 1篇 |
1986年 | 3篇 |
排序方式: 共有152条查询结果,搜索用时 15 毫秒
1.
M F Bellin F Richard P Gobin E Dion F Ghany C Chatelain J Grellet 《Urologic radiology》1992,14(3):168-171
Computed tomographic (CT) renal planimetry was used to study individual renal function in 32 adult patients with urologic disease. CT results were well-correlated to reference methods (r = 0.88, P < 0.001), which were radionuclide studies (N = 9) or separate creatinine clearance (N = 23). The difference between planimetric data and reference methods did not exceed 14% in any case and was less than 10% in 26 cases. 相似文献
2.
Sterling Richard K. King Wendy C. Khalili Mandana Kleiner David E. Hinerman Amanda S. Sulkowski Mark Chung Raymond T. Jain Mamta K. Lisker-Melman M auricio Wong David K. Ghany Marc G. 《Digestive diseases and sciences》2022,67(2):676-688
Digestive Diseases and Sciences - There are limited data on noninvasive methods to identify hepatic steatosis in coexisting hepatitis B virus (HBV) infection. To evaluate the diagnostic performance... 相似文献
3.
Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C 总被引:21,自引:0,他引:21
Promrat K McDermott DH Gonzalez CM Kleiner DE Koziol DE Lessie M Merrell M Soza A Heller T Ghany M Park Y Alter HJ Hoofnagle JH Murphy PM Liang TJ 《Gastroenterology》2003,124(2):352-360
BACKGROUND & AIMS: CCR5Delta32, a 32-base pair deletion of the CC chemokine receptor (CCR) 5 gene, is associated with slowed human immunodeficiency virus disease progression in heterozygotes and protection against infection in homozygotes. A recent study found a higher than expected frequency of CCR5Delta32/Delta32 in patients with hepatitis C virus infection. The roles of other disease-associated chemokine system polymorphisms have not been evaluated in hepatitis C virus infection. METHODS: Six chemokine system polymorphisms (CCR5Delta32, CCR5 promoter 59029-G/A, CCR2 -64I, RANTES [regulated upon activation, normal T cells expressed and secreted] -403 -G/A, and -28 -C/G and stromal derived factor 1 -3'A) were studied in 417 patients with liver diseases (339 with hepatitis C) and 2380 blood donors. The clinical parameters of hepatitis C virus infection were compared between carriers and noncarriers of each genetic variant. RESULTS: The frequency of CCR5Delta32 homozygosity was 0.8% in whites with hepatitis C virus and 1.1% in controls (P = 0.75). The CCR5Delta32 allele was not associated with any of the clinical parameters of hepatitis C virus infection. Hepatitis C virus-seropositive whites with the RANTES -403-A allele were less likely to have severe hepatic inflammation compared with those without (odds ratio, 0.34; P = 0.03). In multivariate analysis, the CCR5 promoter 59029 -A allele was marginally associated with a sustained response to interferon therapy (odds ratio, 3.07; P = 0.048). CONCLUSIONS: In this cohort, the frequency of CCR5Delta32 homozygosity in patients with hepatitis C was similar to controls. The high prevalence of CCR5Delta32 homozygosity in the hepatitis C virus patients of the earlier study likely reflects resistance to human immunodeficiency virus infection in hemophiliacs rather than a susceptibility to hepatitis C virus infection. Expression of CCR5 and RANTES may be important in the modulation of hepatic inflammation and response to interferon therapy in chronic hepatitis C. 相似文献
4.
Soza A Heller T Ghany M Lutchman G Jake Liang T Germain J Hsu HH Park Y Hoofnagle JH 《Journal of hepatology》2005,43(1):67-71
BACKGROUND/AIMS: Currently, there are no effective therapies available for patients with chronic hepatitis C who have failed to respond to optimal interferon alfa-based regimens. The aims of this pilot study were to assess the antiviral activity and safety of interferon gamma in chronic hepatitis C. METHODS: Patients with chronic hepatitis C, genotype 1, who had not responded to or who had relapsed after therapy with interferon alfa and ribavirin were enrolled in a trial of interferon gamma 1b given in doses of 100, 200 or 400 microg subcutaneously three times weekly for 4 weeks. Frequent blood samples were obtained for HCV RNA levels. RESULTS: Fourteen patients were enrolled. Geometric mean HCV RNA levels remained unchanged. Serum aminotransferase levels also did not change, while there were significant decreases in neutrophil counts (-41% from baseline) and hematocrit (-5%). Low grade fever and malaise were common with the first injection of interferon gamma, but no serious side effects were encountered. CONCLUSIONS: Although relatively well tolerated, interferon gamma in doses of 100-400 microg thrice weekly had no effect on HCV RNA levels in patients with chronic hepatitis C who had failed to achieve a sustained response to interferon alfa-based therapies. 相似文献
5.
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders 总被引:6,自引:0,他引:6
Lee WM Dienstag JL Lindsay KL Lok AS Bonkovsky HL Shiffman ML Everson GT Di Bisceglie AM Morgan TR Ghany MG Morishima C Wright EC Everhart JE;HALT-C Trial Group 《Controlled clinical trials》2004,25(5):472-492
The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was designed to determine whether maintenance interferon therapy could slow disease progression in patients who had failed to eradicate hepatitis C virus (HCV) during prior interferon treatment (nonresponders). Ten clinical sites, a virological testing center, and a data coordinating center (DCC) were selected to collaborate in the design and implementation of the final protocol. Eligible patients had been treated previously with interferon for at least 12 weeks, with or without another antiviral, ribavirin, but still had persistent viremia. Because patients had received a variety of prior treatments, and as a perceived benefit of enrollment, we incorporated a Lead-in period of treatment with long-acting pegylated interferon alfa-2a plus ribavirin into the study design, a combination believed to be more effective but not approved by the Food and Drug Administration at the Trial's inception. If patients failed to achieve clearance of virus from the blood after 20 weeks of this Lead-in therapy, they were entered into the main trial at week 24 and randomized to receive either a lower dose of pegylated interferon weekly alone or no further therapy for an additional 3 1/2 years. The original protocol was amended later in three respects to improve enrollment and to adapt to Food and Drug Administration approval of the Lead-in therapy, including allowing patients to proceed directly to the randomized part of the study if treatment resembling the Lead-in had been completed. The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity. 相似文献
6.
7.
Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. 总被引:5,自引:0,他引:5
Glen Lutchman Kittichai Promrat David E Kleiner Theo Heller Marc G Ghany Jack A Yanovski T Jake Liang Jay H Hoofnagle 《Clinical gastroenterology and hepatology》2006,4(8):1048-1052
BACKGROUND & AIMS: Thiazolidinedione (TZD) therapy improves liver histology in nonalcoholic steatohepatitis (NASH) through a mechanism possibly related to its insulin-sensitizing or anti-inflammatory activity. This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH. METHODS: Serum samples from 18 patients with NASH obtained at day 0 and week 48 of therapy during an open-label study of pioglitazone were tested for adiponectin, leptin, interleukin (IL)-1a, IL-6, and tumor necrosis factor (TNF)-alpha levels. Paired liver biopsy specimens were scored (0-4) for steatosis, parenchymal inflammation, cell injury, and fibrosis. RESULTS: Adiponectin levels increased from 3.7 to 10.3 mug/mL at week 48 (P < .01); the levels of the other cytokines were unchanged: TNF-alpha, 9.1 vs 8.8 pg/mL; IL-1a, 3.9 vs 3.4 pg/mL; IL-6, 19.4 vs 13.4 pg/mL; and leptin, 24.8 vs 29.6 ng/mL (P > .05 for all). Pioglitazone therapy was associated with improvements in steatosis (2.5 vs 1.0), parenchymal inflammation (3.3 vs 2.1), cell injury (2.2 vs 0.9), and fibrosis (2.0 vs 1.4). The change in adiponectin level was associated with the improvement in steatosis (P = .03) as well as in a summary NASH activity index score (P = .01). Changes in IL-1, IL-6, TNF-alpha, and leptin levels did not correlate with improvements in the histological features. CONCLUSIONS: Improvements in liver histology during TZD therapy may be modulated by an adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism rather than by changes in proinflammatory cytokines. 相似文献
8.
Assessment of liver fibrosis: palpate, poke or pulse? 总被引:6,自引:0,他引:6
9.
10.